Beijing, Shanghai, Boston, May 8, 2025 — Jacobio Pharma (1167.HK) announced that research on its independently developed SHP2 inhibitor, sitneprotafib, has been published in Clinical Cancer Research (Impact Factor: 10.4). The article details in vitro/in vivo preclinical data and representative cases of patients on the SHP2 inhibitor in combination therapies targeting the RTK/RAS/MAPK pathway and PD-1 blockade therapies . 

The study demonstrates that JAB-3312 significantly enhances the anti-tumor activity of the KRAS G12C inhibitor glecirasib in both treatment-naïve and resistant models. Combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. JAB-3312-osimertinib combination exhibited great efficacy in osimertinib-resistant non-small cell lung cancer models. Besides, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting anti-tumor microenvironment.  

Currently, Jacobio Pharma is conducting a Phase III clinical trial of sitneprotafib in combination with glecirasib, which marks that JAB-3312 is the first SHP2 inhibitor to enter Phase III clinical trials. 

About Sitneprotafib

Sitneprotafib (JAB-3312) is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of sitneprotafib in monotherapy and combination therapies with glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor glecirasib has been approved by China CDE in Feb 2024.  

About Glecirasib  

Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and Europe and breakthrough therapy designation in China.  

About Jacobio Pharma 

Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries. For more information, please visit: http://www.jacobiopharma.com